[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vap---ventilator-associated-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vap---ventilator-associated-pneumonia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,52,74,100,126,158,183,211,240,267],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100613517","early-antibiotics-adaptation-in-severe-pneumoniathe-early-adapt-study-100613517",false,"NCT07267624","EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)","EARLY Antibiotics aDaptation in Ventilator-Acquired-Pneumonia Treatment After Implementation of a Broad-Panel Respiratory Multiplex PCR Test: A Multicenter Randomized Control Trial Conducted In Swiss Intensive Care Units. The EARLY ADAPT Study.","EARLY ADAPT","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old)\n* Hospitalized in intensive care with invasive mechanical ventilation ≥ 48 hours\n* Administration of antimicrobial therapy for suspected VAP at the time of inclusion.\n* Expected survival \\> 96 hours.\n\nExclusion Criteria:\n\n* Enrollment prior to the current trial\n* Participation in an interventional study on the management of AMR that has a direct impact on antibiotic therapy practices.","ALL","18 Years",{"count":20,"type":21},170,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of the study is to determine whether rapid multiplex PCR testing of respiratory samples can reduce exposure to broad-spectrum antibiotics in intensive care unit patients with suspected or confirmed ventilator-associated pneumonia, compared to standard diagnostic methods.\n\nAs secondary objectives, the investigators will study antibiotic management and overall antibiotic consumption, as well as escalation or de-escalation events. The investigators will study the potential clinical impact of using multiplex PCR to see if the length of stay in the intensive care unit is reduced, as well as the duration of mechanical ventilation.",[27,28,29,30,31],"VAP - Ventilator Associated Pneumonia","Antibiotic","Antibiotic Stewardship","Antibiotic Prescribing for Acute Respiratory-tract Infections","Intensive Care (ICU)",[33,34,35,36,37,38],"ventilator Associated Pneumonia (VAP)","antibiotic","PCR multiplex","intensive care","broad spectrum antibiotic","stewardship","NOT_YET_RECRUITING","2026-04-28",{"date":42,"type":43},"2026-04-29","ACTUAL",{"date":45,"type":21},"2026-06-05",{"date":47,"type":21},"2028-06-30",{"name":49,"class":50},"University Hospital, Geneva","OTHER",5,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":18,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100435868","early-identification-of-pathogens-in-children-with-respiratory-tract-infection-by-mechanical-ventilation-using-mngs-100435868","NCT04955821","Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS","Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using Metagenomics Next Generation Sequencing","Inclusion Criteria:\n\n* The time of invasive mechanical ventilation was less than 24 h when admitted to PICU Total duration of invasive mechanical ventilation is over 5 days\n\nExclusion Criteria:\n\n* Participants in other clinical trials in the same period No Informed Consent signed","29 Days",{"count":61,"type":21},400,"OBSERVATIONAL","VAP（Ventilator-associated pneumonia）is the most common complication of mechanical ventilation in severely ill patients. VAP is defined as pneumonia occurring 48 hours after patients receive mechanical ventilation, including pneumonia occurring within 48 hours after extubation. It is one of the important causes of hospital-acquired infection, and the incidence of VAP in children on mechanical ventilation is about 10%, or 7\u002F1000 days of mechanical ventilation, and the overall mortality is 10-24%.Research has so far explained the relationship between bacteria isolated from human biological samples and VAP pathogens. Most studies are limited to the level of bacterial species, and there are few reports on bacterial genotyping, and there is a lack of scientific basis for the pathogenesis of VAP caused by bacteria in ventilator pipeline. The aim of the study is to investigate pathogen of the sputum in deep respiratory tract of patients with mechanical ventilation in PICU by the means of second generation sequencing (NGS).",[27],"2026-02-12",{"date":67,"type":43},"2026-02-17",{"date":69,"type":21},"2026-07-01",{"date":71,"type":21},"2026-12-01",{"name":73,"class":50},"Children's Hospital of Fudan University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100608490","bacteriophage-cocktail-therapy-for-multidrug-resistant-gram-negative-ventilator-associated-pneumonia-100608490","NCT07202234","Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia","A Randomized Controlled Trial of Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia","Inclusion Criteria:\n\n1. Diagnosed with ventilator-associated pneumonia (VAP);\n2. Identified infection with MDR Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa via MROSE evaluation and antimicrobial susceptibility testing (AST) from this or other tertiary hospitals;\n3. Aged 18 to 85 years;\n4. Written informed consent obtained from the patient or legal guardian.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. FiO₂ ≥ 70% or PEEP ≥ 15 cmH₂O;\n3. Hemodynamic instability (vasopressor dose increased by ≥30% in the last 6 hours or norepinephrine \\> 0.5 μg\u002Fkg\u002Fmin);\n4. Known allergy to phage components.","85 Years",{"count":83,"type":21},248,[24],"The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial infections.",[27],[88,89,90],"phage therapy","ventilator-associated pneumonia","phage cocktail","2025-09-23",{"date":93,"type":43},"2025-10-01",{"date":95,"type":21},"2025-11-01",{"date":97,"type":21},"2028-05-31",{"name":99,"class":50},"Chinese PLA General Hospital",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100603602","effect-of-the-aspiration-care-bundle-on-preventing-vap-100603602","NCT07138651","Effect of the Aspiration Care Bundle on Preventing VAP","Yoğun Bakım Hastalarına Uygulanan Aspirasyon Bakım Paketinin Ventilatör İlişkili Pnömoni Gelişimini Önlemeye Etkisi: Yarı Deneysel Çalışma","Inclusion Criteria:\n\n* Patients admitted to the pulmonary intensive care unit\n* Aged 18 years or older\n* Connected to mechanical ventilation via ETT\u002FTT\n* Glasgow Coma Scale score: 8 or higher\n* Remaining in the intensive care unit for at least 24 hours\n* Patients who have not previously been diagnosed with ventilator-associated pneumonia will be included in the study.\n\nExclusion Criteria:\n\n* Transferred from the pulmonary intensive care unit to another clinic\n* Diagnosed with ventilator-associated pneumonia within the first 24 hours\n* Glasgow Coma Scale score fell below 8 during the study\n* Deceased at the time of data collection\n* Patients who developed any complications related to aspiration (atelectasis, hypoxemia, bradypnea, etc.) prior to the study will be excluded from the study.",true,{"count":109,"type":21},60,[24],"Many pharmacological and non-pharmacological interventions are used to prevent ventilator-associated pneumonia (VAP). Nurses are directly responsible for implementing non-pharmacological interventions and therefore have an important role in preventing VAP. The most important non-pharmacological nursing interventions to prevent VAP are hand hygiene and oral care. In addition, the head of the bed should be elevated to 30°-45°, head pressure should be monitored, and subglottic aspiration should be performed. Various care packages have been developed to prevent VAP. It has been determined that these care packages reduce the incidence of VAP. The aim of this study was to investigate the effect of the aspiration care package applied in the intensive care unit on preventing the development of ventilator-associated pneumonia, and it was planned as a quasi-experimental study.",[27,113,114,115,116],"Care","Bundle Care","Aspiration","Nursing Care","2025-08-23",{"date":119,"type":43},"2025-08-29",{"date":121,"type":21},"2025-09-15",{"date":123,"type":21},"2026-09-15",{"name":125,"class":50},"Akdeniz University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100602916","oral-care-layered-enhancement-for-improved-oral-hygiene-in-intensive-care-units-100602916","NCT07129733","Oral Care Layered Enhancement for Improved Oral Hygiene in Intensive Care Units","Oral Care Layered Enhancement for Improved Oral Hygiene in Intensive Care Units: A Stepped-Wedge Cluster Randomized Clinical Trial","ORACLE","Inclusion Criteria:\n\n* All patients who receive mechanical ventilation in the participating intensive care units\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria",{"count":135,"type":21},4800,[24],"The goal of the ORACLE study is to evaluate the impact of implementing a standardized oral hygiene bundle on outcomes in critically ill, mechanically ventilated patients. The primary objective is to determine whether this bundle can increase the number of ventilator-free days compared to the standard of care.",[139,140,141,142,27],"Mechanical Ventilation","Infection Prevention","Oral Care","Oral Hygiene, Oral Health",[144,145,146,147],"Oral care","Oral hygiene","critically ill","mechanical ventilation","2025-08-15",{"date":150,"type":43},"2025-08-19",{"date":152,"type":21},"2025-09-01",{"date":154,"type":21},"2026-11-30",{"name":156,"class":50},"Hospital do Coracao",6,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100512453","hapvap-diagnosis-in-critically-ill-septic-patients-using-a-multiplex-pcr-array-100512453","NCT05952648","HAP\u002FVAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array","HAP\u002FVAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Assay: A Multicenter Randomized Open-Label Trial. THE LIGHTNING STUDY","LIGHTNING","Inclusion Criteria:\n\n* Suspicion of HAP\u002FVAP (clinical\u002Fradiological\u002Flaboratory criteria);\n* Availability to perform tracheal aspirates or broncoalveolar lavage within 1 hour from clinical suspicion\n* Life expectancy ≥ 48 hours\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy,\n* Concomitant participating in other interventional trial\n* Refusal to sign informed consent",{"count":167,"type":21},126,[24],"Multicenter, randomized, controlled, open-label trial to assess if semiquantitative multiplex PCR assay, as compared to conventional microbiology, can reduce the percentage of patients without microbiological diagnosis in the first 24 hours from HAP\u002FVAP suspicion, thus allowing early de-escalation.",[171,27],"HAP - Hospital Acquired Pneumonia","RECRUITING","2025-08-11",{"date":175,"type":43},"2025-08-14",{"date":177,"type":43},"2024-04-03",{"date":179,"type":21},"2026-04-01",{"name":181,"class":50},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",4,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":210},"100521764","lung-infection-in-icu-lung-i3-100521764","NCT06073834","LUNG INFECTION in ICU (LUNG-I3)","LUNG INFECTION in ICU","LUNG-I3","Inclusion Criteria:\n\nAll the following criteria\n\n* Age 18 years or greater\n* Severe ICU patients hospitalized for one of the above diseases:\n\n  * Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\u002FL (\\>18 mg\u002FdL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20)\n  * Severe trauma (level I and II), Injury Severity Score ≥ 25 OR\n  * Burn with TBSA over 20%\n* NAD \\> 0.1 µg\u002Fkg\u002Fmin\n* At least 2 SOFA criteria ≥ 2 points\n\nExclusion Criteria:\n\n* Aspiration pneumonia\n* Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)\n* COPD\n* Smoke inhalation in burn patients\n* Participation in an intervention study\n* Pregnant or breastfeeding women\n* Immunocompromised patients, defined as\n\n  * patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease\n  * hematologic malignancies\n  * solid organ transplantation\n  * HIV infection with or without AIDS\n  * treatment with corticosteroids (\\> 3 months at any dosage or ≥ 1 mg\u002Fkg prednisone equivalent per day for \\> 7 day)\n  * treatment with other immunosuppressive drugs.",{"count":192,"type":21},68,"objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils",[27],[27,196,197,198,199],"Sepsis","Lung Infection","Broncho-alveolar Lavage","ICU","2025-02-10",{"date":202,"type":43},"2025-02-12",{"date":204,"type":43},"2023-12-05",{"date":206,"type":21},"2027-06",{"name":208,"class":209},"BioMérieux","INDUSTRY",1,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":210},"100567011","physiological-effects-and-safety-of-continuous-high-frequency-oscillatory-ventilation-in-mechanical-ventilation-patients-100567011","NCT06662630","Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients","Assessing the Physiological Impact and Safety of Continuous High-Frequency Oscillatory Ventilation in Critically Ill Patients Under Mechanical Ventilation","Inclusion Criteria:\n\n* Patients older than 18 and younger than 90 years;\n* Admitted to the ICU after October 15, 2024, who are intubated and expected to be unable to be extubated within 48 hours due to ARDS, or have atelectasis, or have VAP.\n* Signed informed consent for MetaNeb treatment.\n\nExclusion Criteria:\n\n* Refusal to participate in the proposed study.\n* Age \\\u003C 20 years;\n* Pregnancy;\n* Significant hemodynamic instability defined as an increase of more than 20% in catecholamine doses in the last hour, despite optimization of blood volume, for a target mean blood pressure between 65 and 75 mmHg.\n* Participation in another trial within 30 days prior to meeting eligibility criteria;\n* Severe chronic respiratory disease requiring long-term oxygen therapy or home mechanical ventilation;\n* Pneumothorax;\n* Expected duration of mechanical ventilation \\\u003C 48 hours\n* Decision to refuse life-sustaining treatment.","20 Years","90 Years",{"count":221,"type":21},30,[24],"Mechanical ventilation is an important treatment modality for intensive care unit (ICU) patients, but it also brings a series of problems such as ventilator-associated pneumonia, ventilator-induced lung injury, and atelectasis. Continuous High-Frequency Oscillation (CHFO )is often considered to have a protective effect on the lungs. CHFO provides effective gas exchange at supraphysiological frequencies while minimizing pressure fluctuations, producing tidal volumes smaller than dead space and adjusting around a continuously expanding pressure to optimize end-expiratory lung volume (EELV) by achieving and maintaining lung recruitment. However, the physiological effects and safety of CHFO in critically ill patients on mechanical ventilation lack relevant research. The objective of this research is to assess the feasibility, safety, and efficacy of CHFO in a population of mechanically ventilated critically ill patients.",[225,226,27],"Atelectasis","Acute Respiratory Distress Syndrome",[147,228,229,230],"HFOV","EIT","FRC","2024-11-18",{"date":233,"type":43},"2024-11-20",{"date":235,"type":21},"2024-11-19",{"date":237,"type":21},"2026-10-14",{"name":239,"class":50},"Shanghai Zhongshan Hospital",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":210},"100547645","efficiency-and-safety-of-the-prolonged-use-of-heat-and-moisture-exchangers-in-icu-100547645","NCT06410664","Efficiency and Safety of the Prolonged Use of Heat and Moisture Exchangers in ICU","Safety and Efficiency of the Prolonged (72-hour) Use of a Single Heat and Moisture Exchanger in Adult Mechanically Ventilated Critically Ill and Its Impact on the Lower Respiratory Tract Pathogenic Microbial Colonisation Rate (FILTRex Trial); a Single-centre, Randomised, Controlled Trial","FILTRex","Inclusion Criteria:\n\n1. Age ≥18 years\n2. In-patient in ICU and expected to stay \\> 3 days\n3. Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation ≥ 72h\n4. Clinical Pulmonary Infection score (CPIS) less than six at the baseline 5 No history and symptoms of aspiration at the baseline\n\nExclusion Criteria:\n\n1. Suspected pulmonary infection on admission and in the first 48 hours of mechanical ventilation\n2. Pregnancy\n3. Acute respiratory distress syndrome\n4. Body temperature \\\u003C 32°C\n5. Airway bleeding or other contraindications for the use of HME\n6. An early decision of treatment withdrawal",{"count":249,"type":21},120,[24],"FILTRex is a single-centre, controlled, randomised, prospective, non-inferiority clinical trial to compare the efficiency and safety of prolonged (72-hours) versus standard (24-hours) duration of use for Heat and Moisture Exchange (HME) filters in adult mechanically ventilated critically ill patients",[27],[254,255,256,257],"pneumonia","Heat and Moisture Exchange (HME) filter","VAP bundle in ICU","endotracheal tube occlusion","2024-07-25",{"date":260,"type":43},"2024-07-26",{"date":262,"type":43},"2024-05-01",{"date":264,"type":21},"2026-06",{"name":266,"class":50},"Charles University, Czech Republic",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":287,"leadSponsor":289,"locationsCount":210},"100519582","phase-4-oral-care-with-3-hydrogen-peroxide-oroxid-in-icu---effects-on-the-lower-airway-microbial-colonisation-100519582","NCT06045429","Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation","Effects of Oral Care With 3% Hydrogen Peroxide (Oroxid®) on the Lower Respiratory Tract Microbial Colonisation in Mechanically Ventilated Adult Critically Ill Patients (HyPer-MICROBE Trial); a Single-centre, Randomised, Controlled Trial","HyperMICROBE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. In-patient of ICU and expected to stay \\> 5 days\n3. Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation (MV) ≥ 72h\n4. Clinical Pulmonary Infection score (CPIS) less than 6 at the baseline\n5. No history and symptoms of aspiration at the baseline\n\nExclusion Criteria:\n\n1. ATB therapy of respiratory infection on admission\n2. Suspected pulmonary infection on admission and in the first 48h of mechanical ventilation\n3. Pregnancy\n4. Oral ulcers or injuries\n5. Patient with a history of hydrogen peroxide allergy",{"count":276,"type":21},160,[278],"PHASE4","HyPerMICROBE is a single-centre, controlled, randomised, prospective, superiority clinical trial to compare the efficacy of daily oral care with 3% hydrogen peroxide (Oroxid®) versus standard of care (0.2% chlorhexidine digluconate) on the cumulative incidence of lower respiratory tract microbial colonisation in mechanically ventilated adult critically ill patients.",[27],[254,282,283,284],"hydrogen peroxide","chlorhexidine","respiratory tract microbiome",{"date":260,"type":43},{"date":262,"type":43},{"date":288,"type":21},"2025-12",{"name":266,"class":50}]